Intensity Therapeutics, Inc. (INTS) — 8-K Filings

8-K Filings (23)

• 8-K Filing — Dec 5, 2025
• Intensity Therapeutics Files 8-K — Dec 4, 2025 Risk: low
  Intensity Therapeutics, Inc. filed an 8-K on December 4, 2025, reporting on 'Other Events' and 'Financial Statements and Exhibits'. The filing does not contain
• 8-K Filing — Oct 31, 2025
• Intensity Therapeutics Files 8-K on Shareholder Vote Matters — Oct 23, 2025 Risk: low
  Intensity Therapeutics, Inc. filed an 8-K on October 23, 2025, reporting on a submission of matters to a vote of security holders that occurred on October 22, 2
• Intensity Therapeutics Files 8-K — Sep 10, 2025 Risk: low
  Intensity Therapeutics, Inc. filed an 8-K on September 10, 2025, to report "Other Events." The filing does not contain specific details about the nature of thes
• Intensity Therapeutics Files 8-K — Aug 12, 2025 Risk: low
  Intensity Therapeutics, Inc. filed an 8-K on August 12, 2025, reporting on events that occurred on August 8, 2025. The filing primarily concerns amendments to i
• Intensity Therapeutics Files 8-K — Aug 4, 2025 Risk: low
  Intensity Therapeutics, Inc. filed an 8-K on August 4, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain speci
• Intensity Therapeutics Files 8-K on Shareholder Vote Matters — Jul 18, 2025 Risk: low
  Intensity Therapeutics, Inc. filed an 8-K on July 18, 2025, reporting on a submission of matters to a vote of security holders that occurred on July 17, 2025. T
• Intensity Therapeutics Files 8-K: Material Agreement & Equity Sales — Jun 13, 2025 Risk: medium
  On June 11, 2025, Intensity Therapeutics, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securitie
• Intensity Therapeutics Faces Delisting Concerns — Jun 6, 2025 Risk: high
  Intensity Therapeutics, Inc. filed an 8-K on June 6, 2025, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The compa
• Intensity Therapeutics Faces Delisting Concerns — May 20, 2025 Risk: high
  Intensity Therapeutics, Inc. filed an 8-K on May 20, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The filin
• Intensity Therapeutics Files 8-K on Financials — May 13, 2025 Risk: low
  Intensity Therapeutics, Inc. filed an 8-K on May 13, 2025, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and E
• Intensity Therapeutics Enters Material Definitive Agreement — Apr 25, 2025 Risk: medium
  On April 24, 2025, Intensity Therapeutics, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive
• Intensity Therapeutics Files 8-K — Apr 23, 2025 Risk: low
  Intensity Therapeutics, Inc. filed an 8-K on April 23, 2025, reporting an event on April 22, 2025. The filing is primarily a Regulation FD Disclosure and includ
• Intensity Therapeutics Enters Material Definitive Agreement — Nov 22, 2024 Risk: medium
  Intensity Therapeutics, Inc. announced on November 21, 2024, that it entered into a material definitive agreement. The company, incorporated in Delaware with it
• Intensity Therapeutics Appoints New Chief Medical Officer — Oct 23, 2024 Risk: medium
  Intensity Therapeutics, Inc. announced on October 21, 2024, the appointment of Dr. Robert L. Ferris as Chief Medical Officer and a member of the Board of Direct
• Intensity Therapeutics Files 8-K on Officer Changes and Shareholder Votes — Jul 17, 2024 Risk: medium
  Intensity Therapeutics, Inc. filed an 8-K on July 17, 2024, reporting on the departure of directors or certain officers, election of directors, appointment of c
• Intensity Therapeutics Files 8-K — Jul 3, 2024 Risk: low
  On July 3, 2024, Intensity Therapeutics, Inc. filed an 8-K report detailing a material definitive agreement and financial statements. The company, incorporated
• Intensity Therapeutics Appoints New Director, Loses One — May 24, 2024 Risk: medium
  Intensity Therapeutics, Inc. announced on May 21, 2024, a change in its board of directors. Dr. Jonathan M. Roth, a director since 2021, has resigned. The compa
• Intensity Therapeutics Appoints New Chief Medical Officer — May 15, 2024 Risk: medium
  Intensity Therapeutics, Inc. announced on May 14, 2024, the appointment of Dr. James M. Musser as Chief Medical Officer. Dr. Musser brings extensive experience
• Intensity Therapeutics Enters Material Definitive Agreement — May 10, 2024 Risk: medium
  Intensity Therapeutics, Inc. announced on May 6, 2024, that it entered into a Material Definitive Agreement. The filing does not provide specific details about
• Intensity Therapeutics Faces Delisting Concerns — Apr 19, 2024 Risk: high
  Intensity Therapeutics, Inc. filed an 8-K on April 18, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company, incorp
• Intensity Therapeutics 8-K: Officer/Director Changes, Comp Arrangements — Feb 7, 2024
  Intensity Therapeutics, Inc. filed an 8-K on February 7, 2024, reporting events that occurred on February 6, 2024. This filing primarily concerns changes in dir

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX